About us

FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF WORSENING AND ACUTE DECOMPENSATED HEART FAILURE

Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients.

We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.

Approach

We address a large spectrum of heart failure decompensation

With more than 60 million patients worldwide, heart failure is the only category of cardiovascular disease that continues to grow due to the aging population, increased incidence of diabetes, and persistent non-fatal myocardial infarction. Pulmonary congestion is recognized as the main symptom triggering unscheduled inpatient hospitalizations or outpatient visits to diuresis clinics.

Congestion is not always associated with low cardiac output, rather it is related to the stimulation of neuro-endocrine hormones that leads to excessive renal sodium and water reabsorption. Elevated fluid retention is aggravated in patients with pre-existing chronic kidney disease. Excess body fluid retention not only instigates pulmonary congestion and breathing difficulty, it also causes pulmonary hypertension and impairs the function of the skin, liver, kidney and intestine. A rapid onset of congestion results in acute decompensated heart failure, whereas a gradual development of congestion is associated with the worsening of signs and symptoms of heart failure and currently both conditions have high unmet medical needs.

CRF2 reptide
agonist project

VASOPRESSIN NEUTRALIZING ANTIBODY PROJECT

At AHA 2023, the last results of COR-1167 in a sheep model of Worsening Heart Failure, developed by M. Rademaker (Univ. Otago, NZ) were presented: Furosemide at a dose that promotes natriuresis/diuresis had no effect on cardiac pressures or function. The combination of COR-1167 plus furosemide reduced Left Atrial Pressure, Left Ventricular End Diastolic
Paris (France), 07 September 2023 – Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M1) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma
At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time ! COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor

News